Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
European Journal of Haematology|July 1, 2009
The combined expression of HOXA4 and MEIS1 is an independent prognostic factor in patients with AMLMike Zangenberg, Lykke Grubach, Anni Aggerholm, et al.
Cancers|March 14, 2026
Single-Cell Multi-Omics Identifies Measurable Residual Disease Targets Among Myelodysplasia- and Clonal Hematopoiesis-Related Genes in Acute Myeloid LeukemiaEmma Frasez Sørensen, Caroline Arvé, Jonas K Gronlund, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 28, 2008
Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesisEun-Young Ahn, Ming Yan, Oxana A Malakhova, et al.
Ugeskrift for Laeger|January 29, 2009
[Minimal residual disease in malignant diseases of the blood I. Background and pre-clinical validation]Peter Hokland, Charlotte Guldborg Nyvold, Jesper Stentoft, et al.
Experimental Hematology|March 11, 2014
Delineation of known and new transcript variants of the SETMAR (Metnase) gene and the expression profile in hematologic neoplasmsDinisha Cyril Jeyaratnam, Benjamin Stephan Baduin, Marcus Celik Hansen, et al.
The Lancet Regional Health. Europe|January 23, 2025
Second primary non-myeloid malignancies following intensive treatment for adult acute myeloid leukaemia: a Danish population-based cohort studyNanna Nørtoft Nielsen, Jonas Faartoft Jensen, Joachim Baech, et al.
Ugeskrift for Laeger|February 2, 2024
Nina Andersen, Ahmed Ludvigsen Al-Mashadi, Emelie Hamotal Curovic Rotbain, et al.
Blood|October 5, 2011
Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemiaAnna Staffas, Meena Kanduri, Randi Hovland, et al.
BMC Cancer|November 15, 2022
Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trialRichard Dillon, Shanna Maycock, Aimee Jackson, et al.
British Journal of Haematology|April 17, 2026
Improved survival with fludarabine-based therapies in mixed phenotype acute leukaemia: A population-based study using the WHO 2022 classificationLisa-Maj Christensen, Mikkel Runason Simonsen, Jonas Faartoft Jensen, et al.
Pageof 4